Michael Secora - 01 Feb 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Financial Officer
Signature: /s/ Nathan Hatfield, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 01 Feb 2023
Net transactions value: -$22,820
Form type: 4
Filing time: 03 Feb 2023, 16:14:19 UTC
Previous filing: 17 Nov 2022
Next filing: 17 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+202,428	+34%	$0.000000	790,502	01 Feb 2023	Direct	F1, F2
transaction	RXRX	Class A Common Stock	Award	$0	+7,735	+0.98%	$0.000000	798,237	01 Feb 2023	Direct	F3
transaction	RXRX	Class A Common Stock	Tax liability	$22,820	-2,669	-0.33%	$8.55	795,568	01 Feb 2023	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Award	$0	+404,857		$0.000000	404,857	01 Feb 2023	Class A Common Stock	404,857	$8.55	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2023 and every three months thereafter.
F2	Includes 1,502 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2022.
F3	This RSU vested immediately upon the grant date.
F4	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F5	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.